Accessibility Menu
Novartis Ag logo

Novartis Ag(OTC) NVSEF

Market Cap$278.10BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2003)+325%
5 Year+97%
1 Year+37%
1 Month-5%
$151.42
+0.00%
+0.00Today
Novartis Ag last closing stock price
MetricPriceDate
Last closeUSD 151.922026-08-07
Novartis Ag stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-4.16%USD 158.522026-07-31
1 month-5.05%USD 160.002026-07-08
3 month+6.47%USD 142.692026-05-08
Year to date+13.53%USD 133.822025-12-31
1 year+37.42%USD 110.562025-08-07
3 year+68.88%USD 89.962023-08-08
5 year+96.67%USD 77.252021-08-06
Since inception+324.61%USD 35.782003-06-26

Novartis Ag Financials at a Glance

Market Cap

$278.10BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$54.75B

Net Income (TTM)

$12.64B

EPS (TTM)

$6.63

P/E Ratio

22.79

Dividend

$4.74

Beta (Volatility)

0.06 (Low)

Price

$151.42

Volume

4,528

Open

$151.42

Previous Close

$151.92

Daily Range

$151.42 - $151.42

52-Week Range

$115.50 - $171.29

Estimated Earnings Date

Oct 27, 2026

NVSEF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Novartis Ag

Novartis AG is a global pharmaceutical company based in Basel, Switzerland, established in 1996. The company focuses on the entire lifecycle of healthcare products, from research and development to manufacturing and commercialization, with a strong commitment to innovative medicines and generics.

Products and Services
  • Innovative Medicines: Advanced prescription medications across various therapeutic areas
  • Sandoz: Generic and biosimilar products, including antibiotics and active pharmaceutical ingredients
  • Strategic collaborations: Partnerships for drug development and commercialization
Growth Outlook
  • Revenue of $14.09 billion in Q2 2026, showing strong market demand
  • Net income of $3.19 billion in Q2 2026, reflecting effective cost management
  • Continued investment in R&D, with $2.70 billion allocated in Q2 2026
Financial Highlights
  • Trailing twelve months (TTM) revenue of $54.67 billion, indicating robust sales performance
  • Net profit margin of 23.09% TTM, showcasing operational efficiency
  • Dividend yield of 2.92% TTM, providing attractive returns to shareholders
Novartis AG operates in two main segments: Innovative Medicines and Sandoz. The Innovative Medicines division offers a wide range of advanced prescription medications, addressing critical health issues in areas such as ophthalmology, neuroscience, and immunology. The Sandoz division specializes in generics and biosimilars, ensuring access to essential medications at competitive prices. The company's recent financial performance highlights its resilience and growth potential. The revenue of $14.09 billion in Q2 2026 demonstrates strong market demand, while the net income of $3.19 billion reflects effective cost management strategies. Furthermore, Novartis continues to invest significantly in research and development, with $2.70 billion allocated in the latest quarter, ensuring a pipeline of innovative products for future growth. With a trailing twelve months revenue of $54.67 billion and a net profit margin of 23.09%, Novartis showcases operational efficiency and strong sales performance. The dividend yield of 2.92% offers attractive returns to shareholders, making it an appealing option for potential investors. Overall, Novartis AG stands out as a key player in the pharmaceutical industry, committed to advancing healthcare solutions globally.
AI Generated • Jul 25, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

75,267

CEO

Vasant Narasimhan, MD

Website

www.novartis.com

Headquarters

Basel, BS 4056, CH

NVSEF Financials

Key Financial Metrics (TTM)

Gross Margin

74.29%

Operating Margin

29.86%

Net Income Margin

23.09%

Return on Equity

29.64%

Return on Capital

21.41%

Return on Assets

10.34%

Earnings Yield

4.39%

Dividend Yield

3.12%

Payout Ratio

67.77%

Stock Overview

Market Cap

$278.10BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

1.83B

Volume

4.53K

Avg. Volume

37.12K

Financials (TTM)

Gross Profit

$40.67B

Operating Income

$16.57B

EBITDA

$22.69B

Operating Cash Flow

$18.06B

Capital Expenditure

-$2.11B

Free Cash Flow

$15.96B

Cash & ST Invst.

$7.67B

Total Debt

$48.91B

Novartis Ag Performance Analysis

Novartis Ag annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 42,206,000,000-18.2%
20232023-12-31USD 45,440,000,0007.7%
20242024-12-31USD 50,317,000,00010.7%
20252025-12-31USD 54,532,000,0018.4%
Novartis Ag sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-3.2%
Q42025-12-31-6.4%
Q12026-03-31-4.4%
Q22026-06-309.6%
Novartis Ag annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD 3.17-70.2%
20232023-12-31USD 7.10124.2%
20242024-12-31USD 5.87-17.3%
20252025-12-31USD 7.1521.9%
Novartis Ag sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-2.9%
Q42025-12-31-37.0%
Q12026-03-3128.6%
Q22026-06-303.1%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$14.09B

-5.0%

Gross Profit

$10.49B

-8.9%

Gross Margin

74.47%

N/A

Market Cap

$278.10BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$3.69M

N/A

Employees

75,267

N/A

Net Income

$3.19B

-21.0%

EBITDA

$5.80B

-4.5%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$7.67B

+9.6%

Total Debt

$48.91B

+49.9%

Accounts Receivable

$9.83B

+7.2%

Inventory

$6.21B

-1.6%

Long Term Debt

$39.07B

+62.4%

Short Term Debt

$9.84B

+14.8%

Return on Assets

10.34%

N/A

Return on Invested Capital

18.07%

N/A

Free Cash Flow

$5.43B

-11.1%

Operating Cash Flow

$5.74B

-13.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
RHHVFRoche Holding AG
$460.00+0.90%
NONOFNovo Nordisk A/S
$47.40+1.13%
RHHBFRoche Holding AG
$440.00-0.53%
RHHBYRoche Holding AG
$57.56+0.52%

Trending Stocks

Symbol / CompanyPricePrice Chg
SPCXSpace Exploration Technologies
$131.53-0.01%
ACHRArcher Aviation
$6.34+0.13%
INTCIntel
$97.95-0.04%
NVDANvidia
$219.34-0.02%

Questions About NVSEF

What is the current price of Novartis Ag?

Novartis Ag is trading at $151.42 per share.

What is the 52-week range for Novartis Ag?

Over the past 52 weeks, Novartis Ag has traded between $115.50 and $171.29.

How much debt does Novartis Ag have?

As of the most recent reporting period, Novartis Ag reported total debt of $49.01B.

How much cash does Novartis Ag have on hand?

Novartis Ag reported $7.62B in cash and cash equivalents in its most recent financial results.

What is Novartis Ag’s dividend yield?

Novartis Ag currently has a dividend yield of 3.12%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services